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 An endogenous ligand of the human aryl hydrocarbon receptor promotes 
tumor formation. 
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Activation of the aryl hydrocarbon receptor (AHR) by environmental xenobiotic toxins, 
for instance 2,3,7,8-tetrachlorodibenzo-p-dioxin (dioxin), has been implicated in a 
variety of cellular processes such as embryogenesis, transformation, tumorigenesis and 
inflammation. The identity of an endogenous ligand activating the AHR under 
physiological conditions in the absence of environmental toxins, however, has remained 
enigmatic. We identify the tryptophan (Trp) catabolite kynurenine (Kyn) as an 
endogenous ligand of the human AHR that is constitutively generated by human tumor 
cells via tryptophan-2,3-dioxygenase (TDO), a liver- and neuron-specific Trp-degrading 
enzyme not yet implicated in cancer biology. TDO-derived Kyn suppresses antitumor 
immune responses and promotes tumor cell survival and motility via the AHR in an 
autocrine/paracrine fashion. The TDO-AHR pathway is active in human brain tumors 
and associated with malignant progression and poor survival. As Kyn is produced 
during cancer progression and inflammation in the local microenvironment in amounts 
sufficient for activating the human AHR, these results provide evidence for a novel 
pathophysiological function of the AHR with profound implications for cancer and 
immune biology. 
Degradation of Trp by indoleamine-2,3-dioxygenases 1 and 2 (IDO1/2) in tumors and tumor-
draining lymph nodes inhibits antitumor immune responses1-5 and is associated with a poor 
prognosis in various malignancies6. Inhibition of IDO1/2 suppresses tumor formation in 
animal models1,3 and is currently tested in phase I/II clinical trials in cancer patients7. The 
relevance of Trp catabolism for human tumor formation and progression however remains 
elusive. A screen of human cancer cell lines revealed constitutive degradation of Trp and 
release of high micromolar amounts of Kyn in brain tumor cells, namely glioma cell lines and 
glioma-initiating cells (GIC), but not human astrocytes (Fig. 1a). Surprisingly, IDO1 and 
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IDO2 did not account for the constitutive Trp catabolism in brain tumors (Supplementary Fig. 
1a-e, Supplementary note 1). Conversely, tryptophan-2,3-dioxygenase (TDO), which is 
predominantly expressed in the liver and believed to regulate systemic Trp concentrations6, 
was strongly expressed in human glioma cells (Supplementary Fig. 1b) and correlated with 
Kyn release (Fig. 1b; Supplementary note 2). Pharmacological inhibition or knockdown of 
TDO blocked Kyn release by glioma cells, while knockdown of IDO1 and IDO2 had no effect 
(Fig. 1c,d, Supplementary Fig. 2a, Supplementary note 3), thus confirming that TDO is the 
central Trp-degrading enzyme in human glioma cells. In human brain tumor specimens TDO 
protein expression increased with malignancy and correlated with the proliferation index (Fig. 
1e-h, Supplementary Fig. 2b,c,3a,b; Supplementary note 4,5). As described previously8, 
healthy human brain showed weak TDO staining in the neurons (Fig. 1e). TDO expression 
was not confined to gliomas but was also detected in other types of cancers (Supplementary 
Fig. 3b,c; Supplementary note 6). Reduced Trp concentrations were measured in the sera of 
glioma patients (Fig. 1i). This enhanced systemic Trp degradation, however, did not translate 
into increased Kyn levels (Fig. 1i), most likely because Kyn is taken up by other cells and 
metabolised to quinolinic acid. Indeed, accumulation of quinolinic acid was detected in TDO-
expressing glioma tissue (Fig. 1j, Supplementary Fig. 3d; Supplementary note 7).  
 
Kyn suppresses allogeneic T cell proliferation9. Allogeneic T cell proliferation inversely 
correlated with the Kyn formation by glioma-derived TDO (Fig. 2a, Supplementary Fig. 4a,b; 
Supplementary note 8). Knockdown of TDO in glioma cells (Supplementary Fig. 4c,d; 
Supplementary note 9) restored allogeneic T cell proliferation, while addition of Kyn to the 
TDO knockdown cells prevented the restoration of T cell proliferation (Fig. 2b). Kyn 
concentration-dependently inhibited the proliferation of T cell receptor stimulated CD4+ and 
CD8+ T cells (Supplementary Fig. 4e). In addition, knockdown of TDO resulted in enhanced 
lysis of glioma cells by alloreactive PBMC (Supplementary Fig. 4f). Finally, decreased 
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infiltration with leukocyte common antigen (LCA) positive and CD8+ immune cells was 
observed in sections of human glioma with high TDO expression in comparison to those with 
low TDO expression (Fig. 2c,d), indicating that Kyn formation by TDO may suppress 
antitumor immune responses. In vivo experiments in immunocompetent mice demonstrated 
that tumors expressing TDO grew faster than their TDO-deficient counterparts (Fig 2e; 
Supplementary Fig. 4g,h; Supplementary Note 10). In line with this result, TDO expressing 
tumors displayed a higher proliferation index than TDO-deficient controls (Fig. 2f; Suppl. 
Fig. 4i). TDO activity suppressed antitumor immune responses as evidenced by reduced 
interferon-gamma (IFN-) release of T cells and tumor cell lysis by spleen cells of mice 
bearing TDO-expressing tumors in comparison with mice bearing TDO-deficient tumors (Fig. 
2g,h), thus underscoring that TDO activity suppresses antitumor immune responses in vivo. 
 
We next assessed the autocrine effects of Kyn on glioma cells. While no differences in cell 
cycle progression were detected between controls and glioma cells with TDO knockdown 
(Supplementary Fig. 5a), knockdown of TDO reduced motility and clonogenic survival (Fig. 
3a-c, Supplementary Fig. 5b,c; Supplementary Note 11). This was mediated by Kyn as 
exogenous addition of Kyn restored motility and clonogenic survival in the absence of Trp 
(Fig. 3d,e; Supplementray Fig. 5d,e), suggesting that Kyn increases the motility of malignant 
glioma cells. In GIC sphere formation was enhanced in response to Kyn (Fig. 3f). Finally, 
tumor formation was impaired when TDO knockdown tumors were orthotopically implanted 
in the brains of nude mice, which are devoid of functional T cells (Fig. 3g, Supplementary 
Fig. 5f,g; Supplementary note 12). To analyse whether inhibition of antitumor NK cell 
responses, which are functional in nude mice, by TDO may account for impaired formation of 
TDO knockdown tumors, we compared subcutaneous tumor growth in the presence or 
absence of NK cells. NK cell depletion (Supplementary Fig. 5h) enhanced the growth of both 
control and TDO knockout tumors but did not restore the growth of TDO knockout tumors to 
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that of controls (Fig. 3h). Histochemical analyses revealed that TDO knockout tumors showed 
less mitoses and Ki-67 staining than control tumors (Fig. 3i). Collectively, these data suggest 
that Kyn generated by constitutive TDO activity enhances the malignant phenotype of human 
gliomas in an autocrine manner in the absence of functional antitumor T cell and NK cell 
responses.  
 
To understand the molecular mechanisms underlying the autocrine effects of Kyn on glioma 
cells, we performed a microarray analysis of Kyn-treated glioma cells. Detailed pathway 
analysis revealed broad induction of AHR response genes by Kyn (Fig. 4a ; Supplementary 
Fig. 6a,b, 7; Supplementary note 13). TCDD-inducible poly [ADP-ribose] polymerase 
(TIPARP) and plasminogen activator inhibitor 2 (referred to as PAI-2 or SERPINB2), two 
direct AHR target genes, showed the strongest upregulation after 24 h (Supplementary Fig. 
6a)10-12. These two AHR target genes in addition to another direct AHR target gene, 
cytochrome P450, family 1, subfamily B, polypeptide 1 (CYP1B1) were also among the 6 
most upregulated genes after 8 h (Supplementary Fig. 6a)10,11. The 25 genes with the lowest 
(array) p-values in response to 8 h and 24 h Kyn are regulated by the AHR (Fig. 4a; 
Supplementary. Fig. 6b). The AHR is a transcription factor of the basic helix-loop-helix 
(bHLH) Per-Arnt-Sim (PAS) family, which is activated by xenobiotics such as 
benzo[a]pyrene and 2,3,7,8-tetrachlordibenzodioxin (TCDD)13. Malignant glioma cell lines as 
well as GIC express the AHR constitutively (Supplementary Fig. 6c)14, and upregulation of 
AHR target genes by Kyn was confirmed in two different glioma cell lines (Supplementary 
Fig. 6d,e). Kyn led to translocation of the AHR into the nucleus after 1 h, thus showing an 
immediate effect of Kyn on the AHR (Fig. 4b,c, Supplementary Fig. 8a). In accordance, 
Western blot analyses of Kyn-activated tumor cells showed reduced cytoplasmic localisation 
paralleled by increased nuclear accumulation of the AHR comparable to that induced by 
TCDD (Fig. 4d). In the nucleus the AHR forms a heterodimer with the AHR nuclear 
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translocator (ARNT) that interacts with the core binding motif of the dioxin-response 
elements (DRE) located in regulatory regions of AHR target genes15. Kyn concentration-
dependently induced DRE-luciferase activity in glioma cells with an EC50 of 36.6 µM (Fig. 
4e). AHR activation was unique to Kyn in a panel of Trp catabolites (Supplementary Table 1). 
An ethoxyresorufin-O-deethylase (EROD) assay confirmed the induction of the functional 
AHR target gene cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1) with an 
EC50 of 12.3 µM for Kyn (Supplementary Fig. 8b). Radioligand binding assays using mouse 
liver cytosol from Ahr-proficient and Ahr-deficient mice demonstrated that Kyn binds to the 
AHR with a KD(app) of ≈ 4 µM (Fig. 4f). 
The activation of the AHR and upregulation of AHR-regulated gene expression in response to 
Kyn was inhibited by the AHR antagonist 3,4-DMF (Fig. 4g, Supplementary Fig. 8f,g; 
Supplementary note 14) or knockdown of the AHR (Fig. 4h,i, Supplementary Fig. 8h,i), 
indicating that Kyn is a specific agonist of the AHR. The involvement of the same or similar 
AHR residues in the binding to Kyn, TCDD and 3-MC was confirmed by the fact that 
activation of the AHR by all three ligands was inhibited by 3,4-DMF (Supplementary Fig. 
8f,g; Supplementary note 14). Importantly, the endogenous Kyn production of glioma cells 
was sufficient to activate the AHR, as knockdown of TDO decreased the expression of AHR 
regulated genes (Fig. 4j, Supplementary Fig. 8j,k; Supplementary note 15). As mean Kyn 
concentrations of 37.01 +/- 13.4 µM were measured in U87 xenografts (n=6), sufficient Kyn 
concentrations to activate the AHR were also reached in vivo (Suplementary note 15). 
 
We next assessed whether the tumor-promoting effects of Kyn are mediated by the AHR. Kyn 
failed to induce motility of glioma cells after AHR knockdown (Fig. 5a). Also, the increase in 
clonogenic survival in response to Kyn was abolished in glioma cells with a knockdown of 
the AHR (Fig. 5b,c). Interleukin 1, beta (IL1B), epiregulin (EREG), aldehyde dehydrogenase 1 
family, member A3 (ALDH1A3), interleukin 8 (IL8) and interleukin 6 (IL6) are regulated by 
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Kyn via the AHR in glioma cells and have been reported to promote invasiveness and tumor 
growth, suggesting that these genes may contribute to the autocrine tumor-promoting effects 
of TDO-derived Kyn (Supplementary Note 16). In summary these data indicate that AHR 
signaling is indeed responsible for the autocrine effects of TDO-derived Kyn on tumor cells. 
 
To determine whether TDO also influences antitumor immune responses via the AHR we 
analysed the infiltration of LCA+ and CD8+ immune cells in human glioma sections in 
relation to their AHR expression (Fig. 5d,e).  Infiltration by LCA+ and CD8+ immune cells 
was decreased in sections of human glioma with high AHR expression compared to those 
with low AHR expression (Fig. 5d,e), suggesting that AHR signalling may be involved in 
reducing immune cell infiltration. In accordance with an activation of the AHR by TDO-
derived Kyn, expression of the AHR target gene TIPARP in LCA+ immune cells was 
observed only in sections expressing TDO (Fig. 5f).  To analyse the contribution of host AHR 
expression to tumor growth, we compared the growth of murine tumors with and without Tdo 
expression in Ahr-deficient and Ahr-proficient mice. In Ahr-proficient mice Tdo expression 
strongly enhanced tumor growth in comparison to tumors not expressing Tdo (Fig. 5g). The 
same effect was observed in Ahr-deficient mice, albeit to a much lower extent (Fig. 5g). As 
murine glioma cells express functional AHR (Supplementary Fig. 9a, Supplementary note 
17), these results suggest that the increase in tumor growth mediated by TDO in Ahr-deficient 
mice is due to autocrine effects of TDO on the tumor cells themselves. The finding that TDO 
leads to stronger tumor growth in Ahr-proficient than in Ahr-deficient mice (Fig. 5g), 
indicates that AHR-mediated host effects enhance tumor growth. Staining of LCA+ immune 
cells in the tumors revealed that expression of TDO reduced the infiltration with LCA+ 
immune cells in Ahr-proficient mice, but not in Ahr-deficient mice (Fig. 5h,i), suggesting that 
TDO-mediated suppression of anti-tumor immune responses via the AHR contributes to the 
host effects enhancing the growth of Tdo-expressing tumors. In summary, these results 
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indicate that TDO enhances tumor growth by suppressing the antitumor immune response via 
the AHR. 
 
To assess the effect of AHR activity on the tumor cells themselves, we performed in vivo 
experiments using AHR-proficient and AHR-deficient human glioma cells (Fig 5j). 
Knockdown of the AHR in the glioma cells inhibited tumor growth (Fig.5j, Supplementary 
note 18), underscoring the importance of AHR signaling for the autocrine effects of Trp 
degradation. In line, the AHR knockdown tumors showed less mitoses and a reduced 
proliferative index in comparison to the AHR-proficient control tumors (Fig.5k).   
 
Next we aimed to investigate whether TDO-derived Kyn activates the AHR in human brain 
tumor tissue. Indeed, TDO expression correlated with the expression of the AHR and AHR 
target genes in human glioma tissue (Fig. 6a-d, Supplementary Fig.9d,e; Supplementary note 
19), indicating that constitutive TDO expression in glioma cells produced sufficient Kyn 
levels to activate the AHR.  To address whether the TDO-Kyn-AHR signalling pathway is 
also activated in cancers other than gliomas, we analysed microarray data of diverse human 
tumor entities (Fig. 6e; Supplementary Fig. 10a). Interestingly, TDO expression correlated 
with the expression of the AHR target gene CYP1B1 not only in glioma (Fig. 6d), but also in 
B cell lymphoma, Ewing sarcoma, bladder carcinoma, cervix carcinoma, colorectal 
carcinoma, lung carcinoma and ovarian carcinoma (Fig. 6e; Supplementary. Fig. 10a; 
Supplementary note 20).  This finding indicates that the TDO-Kyn-AHR pathway is not 
confined to brain tumors but appears to be a common trait of cancers.  
Analysis of the Rembrandt database revealed that the overall survival of glioma patients 
(WHO grade II-IV) with an upregulation of TDO, the AHR or the AHR target gene CYP1B1 
was reduced compared to patients with intermediate or downregulated expression of these 
genes (Fig. 6f; Supplementary Fig. 10b; Supplementary note 21)16. Finally, in patients with 
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glioblastoma (WHO grade IV)17, the expression of the AHR targets CYP1B1, IL1B, IL6 and 
IL8, which are regulated by TDO-derived Kyn in glioma cells (Fig. 4j; Supplementary Fig. 
6d,e), were found to predict survival even independent of WHO grade (Fig. 6g; 
Supplementary Fig. 10c), thus further underscoring the importance of AHR activation for the 
malignant phenotype of gliomas. In summary these data suggest that endogenous tumor-
derived Kyn activates the AHR in an autocrine/paracrine fashion to promote tumor 
progression. 
 
Cancer-associated immunosuppression by Trp degradation has to date been attributed solely 
to the enzymatic activity of IDO in cancer cells and tumor-draining lymph nodes. Thus, IDO 
inhibition is currently being evaluated as a therapeutic strategy to treat cancer in clinical 
trials7. We show that TDO is strongly expressed in cancer and equally capable of producing 
immunosuppressive Kyn. In IDO-negative glioma cells, TDO appears to be the sole 
determinant of constitutive Trp degradation, indicating that TDO represents a novel 
therapeutic target in glioma therapy. Furthermore we delineate the importance of constitutive 
Trp degradation to sustain the malignant phenotype of cancer by acting on the tumor cells 
themselves. 
Emerging evidence points towards a tumor-promoting role of the AHR. AHR activation 
promotes clonogenicity and invasiveness of cancer cells14,18. Transgenic mice with a 
constitutively active AHR spontaneously develop tumors19,20 and the repressor of the AHR 
(AHRR) is a tumor suppressor gene in multiple human cancers21. The aberrant phenotype of 
Ahr-deficient mice points to the existence of endogenous AHR ligands22. While different 
endogenously produced metabolites such as arachidonic acid metabolites, bilirubin, cAMP, 
tryptamine and 6-formylindolo[3,2-b]carbazole (FICZ) have been shown to be agonists of the 
AHR23, their functionality has not been convincingly demonstrated in a pathophysiological 
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context such as cancer or immune activation.  The search for endogenous ligands of the AHR 
therefore is ongoing.  
 
We now link these two important pathways contributing to cancer progression by showing 
that Trp catabolism leads to AHR activation and provide evidence of a pathophysiological 
human condition that is associated with the production of sufficient amounts of a functionally 
relevant endogenous AHR ligand. Our results reveal a differential response of primary 
immune cells and transformed cancer cells to AHR-mediated signals, which is in line with 
various toxicological studies using the classical exogenous AHR ligands, TCDD and 3-
MC14,18,24. Exposure to these xenobiotics leads to profound suppression of cellular and 
humoral immune responses24, while also promoting carcinogenesis and inducing tumor 
growth14,18. These cell-specific differences in AHR effects are likely to depend on the 
expression of factors differentially regulating AHR signal transduction such as the AHRR21 as 
well as cell-specific transcription factor crosstalk shaping the response to AHR activation25.   
It is likely that Kyn-mediated activation of the AHR is not only relevant in the setting of 
cancer. For instance, activation of the mouse and human AHR by agonistic ligands induces 
regulatory T cells26-29. Interestingly, Ahr-deficient mice suffer from exacerbated CNS 
autoimmunity in the absence of an exogenous ligand27, while Trp catabolites suppress CNS 
autoimmunity30, suggesting that activation of Trp catabolism represents an endogenous feed-
back loop to restrict inflammation via the AHR. In fact, exogenous Kyn is involved in the 
regulation of immune cells in mice via the AHR31,32. Kyn concentrations sufficient to activate 
the AHR are also generated by IDO in response to inflammatory stimuli (Supplementary Fig. 
11a-c; Supplementary note 22). In a broader context, a significant number of malignancies 
arise from areas of mostly chronic infection and inflammation33, where Trp catabolism in the 
tumor microenvironment is activated and sustains local immune suppression34. Activation of 
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the AHR by Kyn generated in response to inflammatory stimuli may thus constitute a 
previously unrecognized pathway connecting inflammation and carcinogenesis. 
 
Methods Summary 
TDO expression was analysed by immunohistochemistry in human tumors. Its relevance for 
Trp degradation was determined using genetic knockdown or overexpression of TDO. Trp 
and Kyn were measured in cell culture supernatants, human sera and xenograft tissue by 
HPLC. Mixed leukocyte reactions, chromium release, Elispot and staining of immune cells in 
tumor tissues were used to access the immune effects of TDO activity. Cell cycle analysis, 
matrigel and spheroid invasion assays, scratch assays, sphere formation assays and clonogenic 
survival assays were employed to analyse the autocrine effects of TDO activity. Orthotopic 
implantation of human glioma cells with and without stable knockdown of TDO into 
CD1nu/nu mice, s.c. injection of these cells into NK-depleted or wildtype CD1nu/nu mice and 
s.c. injection of murine Tdo-proficient and Tdo-deficient GL261 cells into syngeneic 
C57BL/6N mice were performed to analyse the autocrine and paracrine effects of TDO 
activity in vivo. Microarray analysis of Kyn-treated human glioma cells was performed to 
identify signalling pathways activated by Kyn. Analysis of AHR translocation, DRE-
luciferase assays and radioligand binding assays confirmed activation of the AHR by Kyn. 
Pharmacological inhibition and stable knockdown of the AHR (in vitro and in vivo) proved 
that the effects of Kyn are AHR-dependent. Injection of Tdo-proficient and Tdo-deficient 
tumor cells into Ahr+/+ and Ahr-/- mice was used to address the contribution of host effects to 
TDO-mediated cancer promotion. Finally stainings, mircoarray data and clinical data of 
human tumor tissues were used to analyse whether TDO activates the AHR in human cancers 
and how this affects survival. 
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Full Methods and any associated references are available in the online version of 
the paper at www.nature.com/nature 
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Figure Legends 
Figure 1 TDO degrades Trp to Kyn in human brain tumors. a, Trp (left) and Kyn (right) 
content in the supernatants of human astrocytes (hAs), glioma cell lines and GIC (T323) 
cultured for 72 h and measured by HPLC (n=4). b, Correlation between TDO mRNA and Kyn 
release of human glioma cells measured by quantitative RT-PCR and HPLC (n=4). c, Kyn 
concentrations in the supernatants of U87 glioma cells cultured for 48 h in the presence of  the 
TDO inhibitor 680C91 (black bars), controls (white bars; n=4, P= 0.005, 0.002 and 0.0009 for 
1, 5 and 10 µM TDOI, respectively). d, Kyn release of glioma cells after knockdown of TDO 
(black bars, P = 0.000007, 0.0007 and 0.00006, respectively), IDO1 (dark gray bars) or IDO2 
(light gray bars) by siRNA. (n=3) e, Weak neuronal TDO expression in healthy brain tissue 
(upper panel). TDO expression in glioblastoma (WHO grade IV, lower panel); red: TDO 
staining; * necrosis; arrowheads: border to infiltrated brain tissue. Inset: single tumor cells 
(arrows) infiltrating the adjacent brain tissue. Magnification: 40x, insets 100x. f, TDO 
expression in human glioma sections of different WHO grades. Upper panel: astrocytoma 
grade II (left), astrocytoma grade III (right). Lower panel: oligodendroglioma grade II (left), 
oligodendroglioma grade III (right). Magnification 40x. g, Plot of TDO expression [H-score] 
in brain tumors of increasing malignancy (WHO grade II- IV; grade II n=18, grade III n=15, 
grade IV=35). h, Correlation of the Ki-67 proliferative index with the TDO H-score in 
gliomas of different WHO grades (n = 42). P = 3.169-8.  i, Trp (left) and Kyn (right) 
concentrations in the sera of 24 glioblastoma patients and 24 age- and sex-matched healthy 
controls, measured by HPLC. j, Quantification of quinolinic acid staining in healthy human 
brain tissue (white bar, n=5) and glioblastoma tissue (black bar, n=5). The data distribution in 
(g) and (i) is presented using box plots, showing the 25th and 75th percentile together and the 
median, whiskers represent the 10th and 90th percentile, respectively. 
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Figure 2 Paracrine effects of TDO-mediated Kyn release by glioma cells on immune 
cells.  
a, Correlation of the allogeneic proliferation of PBMC cocultured with different glioma cell 
lines with the Kyn release of the glioma cells (n=3). b, Allogeneic proliferation of PBMC 
cocultured with TDO-expressing control U87 glioma cells (sh-c) in comparison to U87 
glioma cells with a stable short hairpin RNA-mediated knockdown of TDO (sh-TDO) 
(blackbars), with or without 100 µM Kyn, in comparison to PBMC alone (white bars, n=3). c, 
Quantification of LCA+ cells stained in human glioma sections with low TDO expression 
(Histoscore < 150, white bar, n=12) and in human glioma sections with high TDO expression 
(Histoscore ≥ 150, black bar, n=17). d, Quantification of CD8+ cells stained in human glioma 
sections with low TDO expression (Histoscore < 150, white bar, n=10) and in human glioma 
sections with high TDO expression (Histoscore ≥ 150, black bar, n=10). e, Growth of Tdo-
expressing (solid circles) and Tdo-deficient control (open circles) GL261 murine glioma cells 
injected s.c. into the flank of C57BL/6N mice was monitored using metric callipers (n=6). 
Tumor weight was calculated using to the equation: tumor weight (g) = (length (cm) × width 
(cm)2) × 0.5. f, Representative TDO and Ki-67 staining of Tdo-expressing (upper panels) and 
control GL261 tumors (lower panels). g, Interferon-gamma release of T cells of mice with a 
subcutaneous Tdo-expressing tumor (black bar) in comparison to those with a subcutaneous 
Tdo-deficient tumor (white bar) in the presence of glioma lysates measured by Elispot (n=3). 
h,  Lysis of GL261 murine glioma cells by spleen cells of mice with a Tdo-expressing 
subcutaneous GL261 tumor in comparison to those with a subcutaneous Tdo-deficient GL261 
tumor meausured by chromium release (n=4). 
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Figure 3 Autocrine effects of TDO-mediated Kyn release by human glioma cells.  
a, Invasion of sh-c or sh-TDO glioma cells into a collagen matrix. b, Quantification of the 
migrated distances of sh-c (open squares) and sh-TDO (solid circles) cells into a collagen 
matrix (n=3, P=0.004, 0.0005 and 0.01 for 24, 48 and 72 h, respectively). c, Clonogenic 
survival of sh-c and sh-TDO U87 cells (n=3). d, Matrigel boyden chamber assay of normal 
U87 glioma cells in the absence of Trp, with 70 µM Trp, 30 µM Kyn or 60 mM Kyn (n=3). e, 
Clonogenic survival of LN-18 glioma cells in the absence of Trp, with 70 µM Trp, 30 µM 
Kyn or 60 µM Kyn (n=3). f, Sphere formation of GIC in response to 70 µM Kyn (black bars), 
controls (white bars) (n=3) g, Representative cranial MRIs, H&E and nestin stainings of CD1 
nu/nu mice implanted with sh-c (upper panel) or sh-TDO (lower panel) U87 glioma cells. The 
images presented are representative of two independent experiments (n=6). h, Tumor weight 
of sh-c (white bars) and sh-TDO (black bars) U87 glioma cells injected s.c. in the flank of 
CD1 nu/nu  mice, that were treated either with control IgG (IgG) or anti-asialo GM1 antibody 
(ASIALO) for NK cell depletion (n=8). i, Representative sections of the tumors described in 
(h) stained with H&E, (arrows show mitoses, upper panel) and Ki-67 (lower panel). 
 
Figure 4 Kyn activates the AHR. a, Relationship of the 25 genes with the lowest (array) p-
values in U87 cells after 8 h of Kyn treatment to the AHR (red: upregulation, green: 
downregulation). b, Translocation of GFP-tagged AHR into the nucleus of mouse hepatoma 
cells, which do not degrade Trp, after treatment with 50 µM Kyn, 50 µM Trp or 1 nM TCDD, 
measured after 3 h (neg. control: medium). c, Ratios of nuclear to cytoplasmic fluorescent 
intensity in cells with GFP-tagged AHR after 3 h of indicated treatment (neg. control: 
medium, pos. control: 1 nM TCDD, 50 µM Kyn). The data distribution is represented by box 
plots, showing the 25th and 75th percentile together with the median, whiskers represent the 
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10th and 90th percentile, respectively (*P<0.001, one way ANOVA on ranks, followed by 
Dunns’ method). d, AHR Western blots of nuclear and cytoplasmic fractions of control, Kyn-
treated and TCDD-treated human LN-229 glioma cells. e, Dioxin-responsive element (DRE) 
chemical activated luciferase gene expression in U87 glioma cells treated with indicated Kyn 
concentrations. (n=2); TCDD, positive control. f, Radioligand binding assay with indicated 
concentrations of L-3H-Kyn using mouse liver cytosol from Ahr-proficient and Ahr-deficient 
mice. Specific binding was calculated by subtracting the radioactivity measured in Ahr-
deficient cytosol from that of Ahr-proficient cytosol.  (n=4) g, AHR target gene expression in 
LN-18 glioma cells stimulated with 70 µM Kyn and treated with (black bars) or without 
(white bars) the AHR antagonist 3,4-dimethoxyflavone (3,4-DMF, 10 µM, n=4). h, CYP1A1 
mRNA expression in sh-AHR LN-308 glioma cells (black bars) in comparison to controls (sh-
c, white bars) treated with 100 µM Kyn, 1 nM TCDD or controls (n=4). i, AHR target gene 
expression in sh-AHR LN-308 cells (black bars) in comparison to sh-c cells (white bars, n=4). 
j, mRNA expression of AHR target genes in sh-TDO (black bars) U87 glioma cells in 
comparison to sh-c (white bars, n=4). 
 
Figure 5 The autocrine and paracrine effects of TDO-derived Kyn are mediated via the 
AHR  
a, Migration of sh-c LN-308 glioma cells (white bars) and LN-308 glioma cells with 
knockdown of the AHR by two different shRNAs (sh-AHR1, gray bars and sh-AHR2 black 
bars) in the presence or absence of 100 µM Kyn (n=4). b, Clonogenic survival of sh-c (white 
bars) and sh-AHR LN-308 glioma cells (black bars) with or without 100 µM Kyn (n=3). c, 
Clonogenic survival of sh-c (white bars) and sh-AHR LN-18 cells (black bars, n=3). d, 
Quantification of LCA+ cells stained in human glioma sections with low AHR expression 
(Histoscore < 150, white bar, n=10) and in human glioma sections with high AHR expression 
(Histoscore ≥ 150, black bar, n=12). e, Quantification of CD8+ cells stained in human glioma 
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sections with low AHR expression (Histoscore < 150, white bar, n=8) and in human glioma 
sections with high AHR expression (Histoscore ≥ 150, black bar, n=12). f, 
Immunofluorescence stainings of LCA and TIPARP in human glioma sections with low or 
high TDO expression. g, Tumor weight measured 15 days after s.c. injection of murine 
GL261 glioma cells with and without Tdo expression in the flanks of Ahr-proficient (white 
bars) or Ahr-deficient mice (black bars, n=6). h, Representative stainings of LCA+ immune 
cells in the subcutaneous GL261 tumors described above. i, Quantification of LCA+ immune 
cells stained in the subcutaneous Tdo-proficient and Tdo-deficient GL261 tumors in Ahr-
proficient and Ahr-deficient mice presented using box plots, showing the 25th and 75th 
percentile and the median, whiskers represent the 10th and 90th percentile, respectively (n=4). 
j, Growth of AHR-proficient (solid circles) and AHR-deficient (open circles) human LN-308 
glioma cells injected s.c. into the flank of CD1nu/nu mice was monitored using metric 
callipers (n=7). Tumor weight was calculated using the equation: tumor weight (g) = (length 
(cm) × width (cm)2) × 0.5. For statistical analysis see Supplementary note 18. k, 
Representative stainings of the subcutaneous AHR-proficient (sh-c) and AHR-deficient (sh-
AHR) LN-308 tumors with H&E (arrows indicate mitoses), and for AHR expression as well 
as Ki-67 expression. 
 
Figure 6 TDO-derived Kyn activates the AHR in diverse human cancers and AHR 
activation predicts survival in glioma patients 
a, Correlation of TDO expression (red) and AHR expression (brown) in consecutive sections 
of human glioblastoma tissue. Arrows indicate vessels for orientation. Magnification 40x, 
insets 200x. b, Correlation of TDO expression and AHR target gene (CYP1A1) expression in 
diffuse astrocytoma (left) and glioblastoma (right). Magnification 40x, insets 200x. c, 
Correlation between TDO and AHR expression in human glioma tissue based on H-scores of 
TDO and AHR, calculated using Spearman rank correlation (n=26). d, Correlation between 
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TDO and CYP1B1 expression in microarray data of human glioblastoma (n=396) analysed by 
Spearman rank correlation. e, Correlation between TDO and CYP1B1 expression in 
microarray data of human bladder cancer (left, n=58), human lung cancer (middle, n=122) 
and human ovarian carcinoma (right, n=91) analysed by Spearman rank correlation. f, 
Survival probabilities of glioma patients (WHO grade II-IV) with an upregulated expression 
(red) of TDO or the AHR compared to patients with intermediate (blue) or downregulated 
(green) expression of these genes derived from Rembrandt. For statistical analysis see 
Supplementary note 13. g, Survival probabilities of glioblastoma patients with an upregulated 
expression (red) of the AHR target gene CYP1B1 compared to patients with downregulated 
(green) expression of CYP1B1 derived from the glioblastoma data set of The Cancer Genome 
Atlas (TCGA) network (n=362). h, Synoptical figure highlighting the autocrine and paracrine 
effects of TDO-derived Kyn on cancer cells and immune cells via the AHR. 
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